Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
CRIS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.32 - $17.49
Previous CloseN/A
Volume44.55K
Average Volume (3M)33.20K
Market Cap
$20.24M
Enterprise Value$50.42M
Total Cash (Recent Filing)$23.64M
Total Debt (Recent Filing)$35.48M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 20, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.81
Shares Outstanding8,466,957
10 Day Avg. Volume39,469
30 Day Avg. Volume33,202
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.20
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.14
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$20.00Price Target Upside729.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Curis News
PremiumPre-Earnings
Is CRIS a Buy, Before Earnings?
PremiumCompany Announcements
Curis Inc. Reports Positive Q3 2024 Earnings
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCuris reported 10 objective responses out of 19 response-evaluable patients: six patients with complete remission, two patients with CR with either a complete remission with incomplete hematological recovery or a partial hematologic recovery, and two patients with morphologic leukemia free state.
Financial PerformanceCuris reported revenue and EPS that were better than the estimates.
Regulatory ProgressThere is potential for accelerated approval of emavusertib due to the lack of approved or effective therapy for relapsed or refractory primary CNS lymphoma.
Bears Say
RisksRisks: commercial, regulatory, development, manufacturing, financial, liability.
Stock Price TargetThe price target is being lowered to $20 from $26 due to dilution from the offering.
---
Ownership Overview
9.80%
Insiders
3.98% Mutual Funds
28.96% Other Institutional Investors
53.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $2.32 and its highest was $17.49 in the past 12 months.
What is Curis Inc’s market cap?
Curis Inc’s market cap is $20.24M.
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is May 20, 2025 which is in 52 days.
How were Curis Inc’s earnings last quarter?
Currently, no data Available
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -1.24.
How many shares outstanding does Curis Inc have?
Curis Inc has 8,466,957 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Curis Inc?
Currently, no hedge funds are holding shares in CRIS
---
Company Description
Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
---
CRIS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights encouraging clinical trial results and effective cost management, as well as successful fundraising efforts. However, the ongoing net loss and enrollment challenges in the triplet study indicate areas of concern. Overall, the positive aspects of the clinical progress and financial management slightly outweigh the negatives.Read More>---
CRIS Stock 12 Month Forecast
Average Price Target
$20.00
▲(729.88% Upside)
Technical Analysis
Best Analysts Covering CRIS
1 Year
1 Year Success Rate
3/27 ratings generated profit
1 Year Average Return
-16.44%
reiterated a buy rating 6 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -16.44% per trade.
---